HALMED inspected Eris Lifesciences' Ahmedabad Units 1 and 2 from March 9-13, 2026, identifying procedural non-compliances.
The company will execute remediation actions and submit CAPAs to request a follow-on inspection for approval reinstatement.
Minimal impact on existing business but delays commercialization of EU-CDMO product pipeline.